(ADPT) Adaptive Biotechnologies - Ratings and Ratios
DNA Testing, Immunology Assays, Diagnostic Kits Laboratory
ADPT EPS (Earnings per Share)
ADPT Revenue
Description: ADPT Adaptive Biotechnologies
Adaptive Biotechnologies Corp (NASDAQ:ADPT) is a life sciences company focused on providing innovative solutions for the diagnosis and treatment of various diseases. As a player in the Life Sciences Tools & Services sub-industry, the companys performance is closely tied to advancements in genomics, immunology, and biotechnology.
The stock has demonstrated significant price movement, with a current price of $12.15 and a 52-week range of $4.00 to $12.54. The short-term and long-term moving averages (SMA20: $10.92, SMA50: $10.90, SMA200: $8.13) indicate a positive trend, suggesting the stock is gaining momentum. The Average True Range (ATR) of 0.54, representing 4.44% of the current price, implies moderate volatility.
From a fundamental perspective, Adaptive Biotechnologies has a market capitalization of $1.857 billion, indicating a mid-cap status. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, is due to the companys negative earnings. The Return on Equity (RoE) stands at -60.87%, highlighting the companys current unprofitability. Key drivers for the companys valuation include revenue growth, particularly from its collaborations and commercialization of its immuno-sequencing technology, as well as progress in its clinical trials and partnerships.
To assess the companys potential, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense management will be crucial. Additionally, the companys cash burn rate and the time to profitability are essential metrics to monitor. The overall life sciences market trends, regulatory environment, and the competitive landscape will also impact ADPTs stock performance.
In evaluating Adaptive Biotechnologies, its essential to consider the broader context of the life sciences industry, including trends in precision medicine, the adoption of next-generation sequencing technologies, and the competitive positioning of the company within its sub-industry. The companys ability to innovate, form strategic partnerships, and navigate regulatory hurdles will be critical to its long-term success.
ADPT Stock Overview
| Market Cap in USD | 1,966m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2019-06-27 |
ADPT Stock Ratings
| Growth Rating | 50.2% |
| Fundamental | 27.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 134% |
| Analyst Rating | 4.25 of 5 |
ADPT Dividends
Currently no dividends paidADPT Growth Ratios
| Growth Correlation 3m | 72.1% |
| Growth Correlation 12m | 95.6% |
| Growth Correlation 5y | -70.7% |
| CAGR 5y | 20.31% |
| CAGR/Max DD 3y | 0.26 |
| CAGR/Mean DD 3y | 0.62 |
| Sharpe Ratio 12m | -0.81 |
| Alpha | 0.00 |
| Beta | 0.992 |
| Volatility | 57.63% |
| Current Volume | 1434.6k |
| Average Volume 20d | 1647.9k |
| Stop Loss | 12.1 (-5.6%) |
| Signal | -0.43 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-121.2m TTM) > 0 and > 6% of Revenue (6% = 12.3m TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA 8.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 82.70% (prev 156.1%; Δ -73.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -80.5m > Net Income -121.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (152.1m) change vs 12m ago 3.17% (target <= -2.0% for YES) |
| Gross Margin 66.04% (prev 49.93%; Δ 16.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 37.95% (prev 28.86%; Δ 9.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.82 (EBITDA TTM -98.6m / Interest Expense TTM 11.7m) >= 6 (WARN >= 3) |
Altman Z'' -12.61
| (A) 0.34 = (Total Current Assets 261.9m - Total Current Liabilities 92.1m) / Total Assets 496.6m |
| (B) -2.74 = Retained Earnings (Balance) -1.36b / Total Assets 496.6m |
| warn (B) unusual magnitude: -2.74 — check mapping/units |
| (C) -0.21 = EBIT TTM -115.3m / Avg Total Assets 540.8m |
| (D) -4.29 = Book Value of Equity -1.36b / Total Liabilities 317.1m |
| Total Rating: -12.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.53
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -4.94% = -2.47 |
| 3. FCF Margin -48.18% = -7.50 |
| 4. Debt/Equity 1.31 = 1.70 |
| 5. Debt/Ebitda -2.38 = -2.50 |
| 6. ROIC - WACC (= -66.65)% = -12.50 |
| 7. RoE -60.87% = -2.50 |
| 8. Rev. Trend 32.10% = 2.41 |
| 9. EPS Trend 77.74% = 3.89 |
What is the price of ADPT shares?
Over the past week, the price has changed by +3.22%, over one month by +3.30%, over three months by +26.43% and over the past year by +176.89%.
Is Adaptive Biotechnologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADPT is around 12.34 USD . This means that ADPT is currently overvalued and has a potential downside of -3.74%.
Is ADPT a buy, sell or hold?
- Strong Buy: 3
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14 | 9.2% |
| Analysts Target Price | 14 | 9.2% |
| ValueRay Target Price | 13.8 | 7.6% |
Last update: 2025-09-18 04:30
ADPT Fundamental Data Overview
CCE Cash And Equivalents = 197.9m USD (Cash And Short Term Investments, last quarter)
P/S = 9.5795
P/B = 10.9386
Beta = 1.937
Revenue TTM = 205.2m USD
EBIT TTM = -115.3m USD
EBITDA TTM = -98.6m USD
Long Term Debt = 225.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 9.96m USD (from shortTermDebt, last quarter)
Debt = 234.9m USD (Calculated: Short Term 9.96m + Long Term 225.0m)
Net Debt = 41.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.00b USD (1.97b + Debt 234.9m - CCE 197.9m)
Interest Coverage Ratio = -9.82 (Ebit TTM -115.3m / Interest Expense TTM 11.7m)
FCF Yield = -4.94% (FCF TTM -98.9m / Enterprise Value 2.00b)
FCF Margin = -48.18% (FCF TTM -98.9m / Revenue TTM 205.2m)
Net Margin = -59.07% (Net Income TTM -121.2m / Revenue TTM 205.2m)
Gross Margin = 66.04% ((Revenue TTM 205.2m - Cost of Revenue TTM 69.7m) / Revenue TTM)
Tobins Q-Ratio = -1.47 (set to none) (Enterprise Value 2.00b / Book Value Of Equity -1.36b)
Interest Expense / Debt = 1.25% (Interest Expense 2.95m / Debt 234.9m)
Taxrate = 21.0% (US default)
NOPAT = -115.3m (EBIT -115.3m, no tax applied on loss)
Current Ratio = 2.84 (Total Current Assets 261.9m / Total Current Liabilities 92.1m)
Debt / Equity = 1.31 (Debt 234.9m / last Quarter total Stockholder Equity 179.7m)
Debt / EBITDA = -2.38 (Net Debt 41.2m / EBITDA -98.6m)
Debt / FCF = -2.38 (Debt 234.9m / FCF TTM -98.9m)
Total Stockholder Equity = 199.2m (last 4 quarters mean)
RoA = -24.41% (Net Income -121.2m, Total Assets 496.6m )
RoE = -60.87% (Net Income TTM -121.2m / Total Stockholder Equity 199.2m)
RoCE = -27.19% (Ebit -115.3m / (Equity 199.2m + L.T.Debt 225.0m))
RoIC = -57.91% (NOPAT -115.3m / Invested Capital 199.2m)
WACC = 8.74% (E(1.97b)/V(2.20b) * Re(9.67%)) + (D(234.9m)/V(2.20b) * Rd(1.25%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.57%
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -98.9m)
EPS Correlation: 77.74 | EPS CAGR: 36.59% | SUE: 1.91 | # QB: 2
Revenue Correlation: 32.10 | Revenue CAGR: 7.85% | SUE: N/A | # QB: None
Additional Sources for ADPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle